8legs: Eli lilly and company

Your Followed Topics

#1 out of 557.14%

Latest development shows high interest in GLP-1 weight loss jabs despite licensing delays and safety concerns.
Retatrutide, dubbed the 'triple-G' or 'Godzilla' of weight loss, targets three hormone receptors for appetite suppression.
People report severe side effects, including anxiety, heart palpitations, and sleep disturbances, after dosing issues.
Unlicensed and counterfeit versions are circulating as licensed access remains years away, raising safety concerns.
Stimulating media attention persists as celebrities helped popularize GLP-1 jabs, fueling demand.
Experts warn that unregulated supply chains and unsafe dosing can pose serious health risks to users.
Trials show strong weight loss results, but licensing and access remain years away.
A rising number of online forums report adverse experiences, including nausea and anxiety.
Licensed access for GLP-1 jabs is expected to lag behind demand, contributing to the counterfeit market.
The LADbible report frames patient safety and regulatory oversight as central concerns amid rapid pharmacotherapy advances.
The piece notes that Reta’s licensing is not expected until late 2027 or 2028, delaying formal access.

Vote 0

#2 out of 5

The FDA approved orforglipron, the first non-peptide GLP-1 agonist, marketed as Foundayo.
Orforglipron is a small molecule designed to activate the GLP-1 receptor, unlike injectable peptide therapies.
Researchers used Cryo-EM to map the GLP-1 receptor’s binding pocket, guiding molecule design.
AI-assisted retrosynthesis helped chemists find scalable routes to manufacture orforglipron.
Orforglipron offers a more convenient and cheaper alternative to injectable GLP-1 therapies.
The article notes Wegovy’s injectable form and the new oral option as a potential shift in obesity treatment.
The discovery traced the receptor to a 463-amino-acid protein that GLP-1 binds.
Foundayo's development blended human research with AI tools to achieve viability.
The article cites a 72-week trial showing meaningful weight reduction with no significant side effects.

Vote 0

#3 out of 5

Lilly is using GLP-1 windfall strength to fund a broader dealmaking strategy across multiple disease areas.
Jacob S. Van Naarden, Lilly’s EVP and head of oncology, now also leads corporate development to sharpen dealmaking.
Lilly plans to spend up to $25 billion on up to eight acquisitions this year.
The company’s market capitalization is around $1 trillion, up from $190 billion in 2021.
Lilly is diversifying beyond its traditional early bets to include broader opportunities across several therapeutic areas.
Lilly’s 2026 deals include a $1.9 billion collaboration with Ascidian Therapeutics for kidney diseases.
Lilly aims to redeploy capital across oncology, neuroscience, cardiometabolic health and immunology.
Lilly’s leadership says the size of deals hinges on science quality and patient impact, not arbitrary limits.
Lilly joined the trillion-dollar club as it grows into the world’s largest pharmaceutical company.
The strategy shift reflects Lilly’s transition from early bets to larger, more certain investments.

Vote 0

#4 out of 5

Illinois hospitals urge Pritzker to sign the 340B bill promptly to avert Eli Lilly drug-discount disruptions.
The Crain's Chicago Business report frames the push as critical for hospital cost management and patient access.
The article ties the lobbying effort to influence from powerful Chicago-area families and political dynamics.
Billholders warn that delays risk Eli Lilly disclosing or altering pricing discounts for hospitals.
The report places the 340B legislation within a broader national debate over drug pricing and access.
No new details on the bill's specific provisions are provided in the excerpt.
The article appears in Crain’s Chicago Business under Health Care with a local focus on Illinois.
The piece situates the issue within ongoing debates about nonprofit and hospital financing structures.
The report is dated June 3, 2026, indicating a contemporaneous legislative moment.

Vote 0

#5 out of 5

Lilly will halve its planned €2.3 billion investment in Germany, directing funds to the U.S. instead.
The German weight‑loss injections plant in Alzey will begin operations in 2027, with reduced capacity.
Ricks said the scrapped investment could go to Pennsylvania or a new U.S. site, with Europe still in consideration.
Germany’s cost caps in statutory health insurance helped drive the reconsideration of the investment plan.
Over a billion euros has already been invested in the Alzey site prior to the 2027 operations start.
Ricks emphasized that the U.S. offers the most sense for Lilly’s growth plans.
Lilly’s decision aligns with broader shifts in multinational investment amid policy changes in Europe.
The Alzey plant is planned to operate at a reduced scale, affecting job projections.
No final decision has been made on the exact new site, with U.S. options under consideration.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.